新着動画一覧

(SLB, BIOD, INSM) CRWENewswire Stocks In Action

Insmed Inc - INSM - reported that the FDA has lifted the clinical hold previously placed on ARIKACE (liposomal amikacin for inhalation) in patients with non-tuberculous mycobacteria lung disease. Schlumberger Ltd - SLB - posted full-year 2011 revenue of $39.54 billion versus $27.45 billion in 2010. and lastly; Biodel Inc - BIOD - reported that the European Medicines Agency’s Committee for Orphan Medicinal Products has recommended that Biodel’s Stabilized Glucagon for the treatment of congenital hyperinsulinism be granted Orphan Medicinal Product Designation. ********************************* THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! (Read Full Disclaimer at http://www.crwenewswire.com/disclaimer)

投稿者： karmastock
投稿日時：2012-01-21 03:45:46.0
視聴回数：340回
お気に入り登録：0
カテゴリ： ビジネス全般  
タグ： INSM   SLB   BIOD   Nasdaq:INSM   NYSE:SLB   Nasdaq:BIOD